517
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Biogen's recently active trials. Comparator arms are excluded.
- Omaveloxolone10 trials
- Felzartamab8 trials
- Nusinersen6 trials
- Litifilimab5 trials
- Tofersen4 trials
- Diroximel Fumarate4 trials
Upcoming readouts
Next primary completion dates among Biogen's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- May 2027PREVAIL: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Neph…Phase 3
- Nov 2027BRAVE: A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Child…Phase 3
- Jan 2028GRAVITATE: A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults W…Phase 2
- Feb 2028TRANSPIRE: A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Wh…Phase 2
- Jun 2028SOLAR: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants…Phase 3
- Nov 2028STELLAR-1: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Befo…Phase 3
Top therapeutic areas
Conditions studied most often across Biogen's recently active trials.
- Muscular Atrophy, Spinal11 trials
- Friedreich Ataxia5 trials
- Multiple Sclerosis4 trials
- Renal Insufficiency, Chronic4 trials
- Diabetes Mellitus, Type 24 trials
- Amyotrophic Lateral Sclerosis3 trials
Biogen pipeline by phase
The main study drugs across 27 active trials Biogen leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 37 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Felzartamab | 6 | 4 | Dec 2026 est. | NCT07444489 · NCT06962800 · NCT06935357 |
| Litifilimab | 5 | — | Sept 2026 est. | NCT06044337 · NCT05352919 · NCT04961567 |
| SalanersenBIIB115 | 4 | 3 | Jun 2028 est. | NCT07444476 · NCT07444450 · NCT07221669 |
| Nusinersen | 2 | 1 | Sept 2027 est. | NCT05067790 · NCT06555419 |
| Omaveloxolone | 2 | 1 | Nov 2027 est. | NCT06953583 · NCT06054893 |
| BIIB017 (peginterferon beta-1a) | 1 | — | May 2027 est. | NCT03958877 |
| Diroximel Fumarate | 1 | — | Jul 2034 est. | NCT07483632 |
Phase 21 drug
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Diranersen | 1 | — | — | NCT05399888 |
Phase 13 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| BIIB142 | 1 | 1 | — | NCT07133828 |
| BIIB144 | 1 | 1 | Jun 2028 est. | NCT07662148 |
| BIIB145 | 1 | 1 | Feb 2027 est. | NCT07225517 |
Phase 41 drug
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Tofersen | 2 | — | May 2027 est. | NCT07223723 · NCT04856982 |
Derived from 27 active trials Biogen leads; 27 name an intervention, folding into 12 phased drugs. This is ComplyRx's reading of the registry, not Biogen's own pipeline disclosure.
Biogen trials
The 50 most significant of Biogen's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| TOPAZ-2A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567Litifilimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 562 est. | 27 Sept 2026 |
| TOPAZ-1A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241Litifilimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 548 est. | 30 Sept 2026 |
| AMETHYSTA 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusNCT05531565Litifilimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 450 est. | 20 Oct 2026 |
| A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)NCT05925049Natalizumab | — | Not yet scored | OngoingActive, not recruiting | 400 est. | 31 Oct 2026 |
| TRANSCENDA Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)NCT06685757Felzartamab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 132 est. | 1 Dec 2026 |
| A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult ParticipantsNCT07225517BIIB145 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 104 est. | 2 Feb 2027 |
| STANDARDObservational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)NCT04317794Nusinersen Sodium Injection | — | Not yet scored | OngoingActive, not recruiting | 74 est. | 5 Feb 2027 |
| A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting ZuranoloneNCT07398469Zuranolone | — | Not yet scored | OngoingRecruiting | 300 est. | 29 Mar 2027 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877BIIB017 (peginterferon beta-1a) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 152 est. | 20 May 2027 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)NCT07223723Tofersen | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 12 est. | 26 May 2027 |
| PREVAILA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)NCT06935357Felzartamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 454 est. | 31 May 2027 |
| ATLASA Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 MutationNCT04856982Tofersen | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 158 est. | 7 Aug 2027 |
| Pediatric Spinal Muscular Atrophy (SMA) China RegistryNCT05042921 | — | Not yet scored | OngoingActive, not recruiting | 600 est. | 2 Sept 2027 |
| ASCENDA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)NCT05067790Nusinersen | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 45 est. | 24 Sept 2027 |
| PIERRE-PKA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)NCT06555419Nusinersen | Phase 1 | Locked · track to reveal | OngoingRecruiting | 78 est. | 30 Sept 2027 |
| BRAVEA Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's AtaxiaNCT06953583Omaveloxolone | Phase 3 | Locked · track to reveal | OngoingRecruiting | 255 est. | 16 Nov 2027 |
| GRAVITATEA Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldNCT07722546Felzartamab | Phase 2 | Not yet scored | OngoingRecruiting | 60 est. | 31 Jan 2028 |
| TRANSPIREA Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationNCT07219043Felzartamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 81 est. | 10 Feb 2028 |
| Adult Spinal Muscular Atrophy (SMA) China RegistryNCT05618379 | — | Not yet scored | OngoingActive, not recruiting | 200 est. | 1 Jun 2028 |
| A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a PlaceboNCT07662148BIIB144 | Phase 1 | Not yet scored | OngoingRecruiting | 48 est. | 19 Jun 2028 |
| SOLARA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With RisdiplamNCT07444476Salanersen | Phase 3 | Locked · track to reveal | OngoingRecruiting | 90 est. | 23 Jun 2028 |
| STELLAR-1A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)NCT07221669Salanersen | Phase 3 | Locked · track to reveal | OngoingRecruiting | 30 est. | 28 Nov 2028 |
| AMETHYST LTEA Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusNCT06044337BIIB059 (litifilimab) | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 306 est. | 26 Jun 2029 |
| STELLAR-2A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecNCT07444450Salanersen | Phase 3 | Locked · track to reveal | OngoingRecruiting | 42 est. | 27 Jul 2029 |
| A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own DoctorsNCT06623890Omaveloxolone | — | Not yet scored | OngoingRecruiting | 300 est. | 1 Oct 2029 |
| PROMINENTA Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)NCT06962800Felzartamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | 28 Jan 2030 |
| EMERALDAn Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT05352919Litifilimab | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 864 est. | 29 Mar 2030 |
| BOLDA Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldNCT06054893Omaveloxolone | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 33 est. | 4 Jun 2030 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436Diroximel Fumarate | — | Not yet scored | OngoingActive, not recruiting | 1,178 est. | 17 Jan 2031 |
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)NCT07444489Felzartamab | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 201 est. | 28 May 2031 |
| A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene AbeparvovecNCT05575011BIIB115 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 62 est. | 14 Nov 2031 |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)NCT05658497Diroximel Fumarate | — | Not yet scored | OngoingRecruiting | 908 est. | 6 Jul 2032 |
| A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their BabiesNCT05789758 | — | Not yet scored | OngoingRecruiting | 20 est. | 31 Oct 2032 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)NCT05767736Diroximel Fumarate | — | Not yet scored | OngoingActive, not recruiting | 10,500 est. | 1 Dec 2032 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)NCT07259980Tofersen | — | Not yet scored | OngoingRecruiting | 125 est. | 30 Dec 2033 |
| VOYAGEA Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)NCT07483632Diroximel Fumarate | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 185 est. | 28 Jul 2034 |
| A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesNCT06628687Omaveloxolone | — | Not yet scored | OngoingRecruiting | 10 est. | 30 Apr 2035 |
| A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years OldNCT07133828BIIB142 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 78 est. | 6 Aug 2026 |
| A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their PregnancyNCT07047820Zuranolone | — | Not yet scored | Completed | 305 est. | 2 Aug 2026 |
| ONWARDA Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)NCT04729907Nusinersen | Phase 3 | Locked · track to reveal | Completed | 115 est. | 30 Jul 2026 |
| A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldNCT06064929Felzartamab | Phase 1 | Locked · track to reveal | Completed | 14 est. | 24 Jun 2026 |
| SOLSTICELong-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis PigmentosaNCT03584165BIIB111 | Phase 3 | Locked · track to reveal | Completed | 277 est. | 22 Jun 2026 |
| A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55NCT07297199Omaveloxolone | Phase 1 | Locked · track to reveal | Completed | 70 est. | 1 May 2026 |
| CELIAA Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeNCT05399888Diranersen | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 416 est. | 11 Mar 2026 |
| A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different WaysNCT06741657Litifilimab | Phase 1 | Locked · track to reveal | Completed | 404 est. | 10 Mar 2026 |
| LUMAA Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80NCT05348785BIIB122 | Phase 2 | Locked · track to reveal | Completed | 650 est. | 9 Mar 2026 |
| A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy AdultsNCT06454721[89Zr]Zr-DFO-Diranersen | Phase 1 | Locked · track to reveal | Completed | 5 est. | 5 Mar 2026 |
| FUSIONA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520BIIB091 | Phase 2 | Locked · track to reveal | Completed | 127 est. | 10 Feb 2026 |
| A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55NCT07149415Omaveloxolone | Phase 1 | Locked · track to reveal | Completed | 22 est. | 16 Oct 2025 |
| RESPONDA Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)NCT04488133Nusinersen | Phase 4 | Locked · track to reveal | Completed | 46 est. | 9 Oct 2025 |